Bionano Genomics, Inc. (BNGO)

Current Report Filed: 2026-05-06

Key Insights

Executive leadership transition: R. Erik Holmlin terminated as President and CEO effective immediately, with Board Chairman Albert Luderer appointed as interim CEO, signaling potential strategic or operational concerns at the company.
Interim CEO is 77 years old with extensive diagnostic industry experience but is already serving as CEO at another private company (Indi Molecular) since 2013, raising questions about divided attention and commitment duration to this role.
Active CEO search underway: The company intends to promptly identify a permanent CEO, indicating this is a temporary interim arrangement and suggesting investors should expect further leadership announcements in coming months.
Luderer's compensation as interim CEO is $600,000 base salary plus up to $400,000 bonus (pro-rated) plus $4,000/month housing/travel stipend, representing a significant cost for interim leadership that will be replaced.

Current Report Filed: 2026-03-23

Key Insights

Bionano Genomics reported its Q4 2025 financial results, providing investors with an update on the company's recent performance and progress.
The company's revenue and earnings numbers showed strong year-over-year growth, indicating continued momentum in the business.
Bionano highlighted several key strategic initiatives and product developments that position the company for future success in the genomics market.

Annual Report Filed: 2026-03-23

Key Insights

Bionano Genomics reported a significant increase in convertible debt and warrants, indicating potential dilution for shareholders.
The company disclosed plans for a workforce reduction, which could impact future operations and growth.
Bionano's revenue from the Americas region, its primary market, showed a notable decline year-over-year, raising concerns about sales performance.

Insider Trading Filed: 2026-02-18

Key Insights

The reporting person, R. Erik Holmlin, who is the President and CEO of Bionano Genomics, Inc. (BNGO), has reported a disposition of 51 shares of common stock to satisfy tax withholding obligations upon the vesting of a restricted stock unit (RSU) award.
This transaction appears to be a routine, non-discretionary event related to the settlement of an RSU award and does not necessarily indicate any broader sell-side activity by the reporting person.
The reporting person continues to hold 1,657 shares of common stock, indicating ongoing alignment with shareholder interests.

Insider Trading Filed: 2026-02-18

Key Insights

The reporting person, Mark Oldakowski, the Chief Operating Officer of Bionano Genomics, Inc. (BNGO), has reported the withholding of 20 shares of common stock to satisfy his tax withholding obligations upon settlement of a restricted stock unit (RSU) award.
This transaction suggests that the reporting person is taking steps to manage his equity compensation and tax obligations, which may indicate confidence in the company's future performance.
The reported transaction is relatively small in size, suggesting it is a routine event and not indicative of any significant changes in the reporting person's overall ownership or strategy.

Insider Trading Filed: 2026-02-18

Key Insights

Alka Chaubey, the Chief Medical Officer of Bionano Genomics, Inc. (BNGO), disposed of 18 shares of common stock on February 17, 2026 to satisfy tax withholding obligations upon settlement of a restricted stock unit (RSU) award.
The reported transaction represents a relatively small portion of Chaubey's total beneficial ownership, which remains at 644 shares of common stock.
This routine insider transaction does not indicate any significant change in Chaubey's position or outlook on the company, and is likely a standard practice for managing equity-based compensation.

Insider Trading Filed: 2026-02-18

Key Insights

The reporting person, Jonathan V. Dixon, who is the General Counsel of Bionano Genomics, Inc. (BNGO), reported a sale of 6 shares of common stock on February 17, 2026 to cover tax withholding obligations on vested restricted stock units (RSUs).
The sale represents a small portion of the reporting person's total beneficial ownership, which remains at 263 shares following the transaction.
Insider transactions, especially small sales to cover tax obligations, are generally considered routine and not indicative of any significant changes in the reporting person's long-term view of the company.

Insider Trading Filed: 2026-02-18

Key Insights

Insider Mark Adamchak, the Principal Accounting Officer, made a small direct sale of 3 shares of Bionano Genomics common stock on February 17, 2026 to cover tax withholding obligations from the vesting of a restricted stock unit (RSU) award.
The transaction represents a negligible amount of Adamchak's overall beneficial ownership, which remains at 260 shares directly held.
This insider transaction appears routine and not indicative of a significant change in Adamchak's position or outlook on the company.

Insider Trading Filed: 2026-02-04

Key Insights

The CEO R. Erik Holmlin acquired 69,484 stock options on February 2, 2026, exercisable at $1.27 per share and vesting over 48 months.
The option grant suggests the CEO's confidence in the company's long-term growth and aligns his interests with shareholders.
Insider buying activity is generally seen as a positive signal for the stock's future performance.

Insider Trading Filed: 2026-02-04

Key Insights

The reporting person, Jonathan V. Dixon, was granted 26,117 stock options with an exercise price of $1.27 on February 2, 2026, vesting monthly over 4 years.
This indicates that the company is providing long-term equity incentives to its General Counsel, aligning their interests with shareholders.
The relatively low exercise price of $1.27 suggests the options were granted at or near the current market price, rather than at a discount.

Insider Trading Filed: 2026-02-04

Key Insights

The reporting person, Mark Oldakowski, who is the Chief Operating Officer of Bionano Genomics, Inc. (BNGO), acquired 27,737 stock options at an exercise price of $1.27 on 2026-02-02.
The stock options granted to Oldakowski vest monthly over a 48-month period, indicating a long-term incentive alignment between the executive and the company.
Insider buying by Bionano's COO suggests confidence in the company's future prospects and aligns with the overall positive sentiment around Bionano's growth and execution.

Insider Trading Filed: 2026-02-04

Key Insights

Alka Chaubey, the Chief Medical Officer of Bionano Genomics, Inc. (BNGO), has acquired 27,737 stock options with an exercise price of $1.27 and a vesting period of 4 years.
This transaction suggests that Chaubey is bullish on the company's future prospects and is willing to invest in its long-term growth.
The timing of the option grant, which is on February 2, 2026, suggests that the company is providing equity-based incentives to its executives to align their interests with those of shareholders.

Insider Trading Filed: 2026-02-04

Key Insights

Mark Adamchak, the Principal Accounting Officer of Bionano Genomics, Inc. (BNGO), has been granted 10,890 stock options with an exercise price of $1.27, vesting in full on the one-year anniversary of the grant date.
The stock option grant suggests that the company is incentivizing its key accounting personnel to remain with the company and continue contributing to its long-term success.
Insider transactions, such as this stock option grant, can provide insight into management's confidence in the company's future prospects.

Current Report Filed: 2026-01-12

Key Insights

Bionano Genomics, Inc. has reported preliminary financial results for Q4 and fiscal year 2025, which investors will be closely watching.
The filing does not provide details on revenue, margins, or guidance, but a press release with these key financial metrics is attached.
Investors should review the press release for signs of strong or weak performance, as this could impact the stock price.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information